---
schema_version: "secwatch.filing_event.v1"
accession: "0001720580-26-000006"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:40:13.479323+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio reports Q4 2025 net loss $30.5M; Phase 1 prula-cel enrollment momentum; cash $158.5M

## Summary
- Net loss Q4 2025: $30.5M ($2.94 per diluted share) compared to $28.7M ($5.06) in Q4 2024.
- Full-year 2025 net loss $116.8M ($16.95 per share) vs $117.1M ($21.33) in 2024.
- Cash, equivalents & investments $158.5M at Dec 31, 2025; expected to fund ops into H2 2027.
- Phase 1 prula-cel autoimmune enrollment ahead; next update H1 2026; pivotal study H2 2026 subject to FDA.
- ADI-212 regulatory filing for mCRPC expected Q3 2026; Phase 1 enrollment Q4 2026.

## SEC filing metadata
- accession: 0001720580-26-000006
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/0001720580-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/acet-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001720580-26-000006
- JSON: https://secwatch.observer/filing/0001720580-26-000006.json
- Plain text: https://secwatch.observer/filing/0001720580-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.